Source: PR Newswire Crown Laboratories, ("Crown"), a leading, fully integrated, global skincare company and a Hildred Capital Management LLC ("Hildred") portfolio company, and L Catterton, the largest global consumer-focused private equity firm, today announced that they have entered into a definitive agreement under which Crown will acquire StriVectin. The transaction is expected…...
Cassiopea SpA and Sun Pharma Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada
Source: Cassiopea Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries…...
Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea
Source: GlobeNewswire Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced an agreement with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) for the collaborative development and commercialization of the DFD-29 program (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey…...
Biogen’s aducanumab crosses FDA finish line just in time to save its business
Source: Fierce Pharma The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. The FDA’s approval on Monday is set to cause a ripple effect among drugmakers and researchers studying the elusive disease, the sixth leading cause of death in the U.S., and comes after months of intense controversy over…...
Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®
Source: GlobeNewswire The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical’s seventh marketed dermatology product Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered…...
Fortress Biotech’s Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne
Source: Globe Newswire Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, in-licensed and launched an oral isotretinoin under the brand name Accutane® (isotretinoin capsules USP) in the U.S. Accutane is an oral medication that is indicated for the treatment of…...
MedTech FDA clears novel neck collar to help protect student athletes’ brains from sports-related injuries
Source: FierceBiotech The FDA has cleared a new type of device worn around the back of the neck by athletes ages 13 and up, to help protect them from brain injuries caused by typically lighter, but repeated, impacts during sports. The Q-Collar, developed by Q30 Innovations, doesn’t replace helmets…...
UnitedHealth Group’s Optum to buy Change Healthcare for $13B
Source: FierceHealthcare UnitedHealth Group's Optum unit has agreed to buy Change Healthcare for $7.84 billion in cash plus about $5 billion in debt, the companies said on Wednesday. The acquisition will strengthen the insurer's portfolio of healthcare technology services and capabilities. Change Healthcare will join with OptumInsight to provide software…...
Arcutis eyes $100M IPO to bankroll dermatology programs
Source: FierceBiotech Dermatology player Arcutis Biotherapeutics set up shop in 2016 but stayed under the radar until early last year. Now, with a trio of clinical-stage programs and more than $160 million in the bank, the company is looking to hit the street with a $100 million IPO. The Los…...
"I cannot say enough great things about Angel and my experience with her and QFR Solutions. From the time she initially reached out to me until even after I was hired, Angel was in constant contact with me and always kept me updated on what was going on. She was…...